Home › Compound Library › 4-AcO-DMT (Psilacetin)

4-AcO-DMT (Psilacetin)

Psychedelicoral · inferred

Synthetic O-acetylated prodrug of psilocin, the active metabolite of psilocybin. Rapidly deacetylated to psilocin in vivo, producing qualitatively identical effects to psilocybin mushrooms. Yields ~70% of the psilocin exposure of equimolar psilocybin. Effects last 4-6 hours. Not scheduled in many jurisdictions despite pharmacological equivalence to psilocybin.

Projected serum levels — 20 mg, as needed (shown daily)

4-AcO-DMT (Psilacetin) (precursor)
4-AcO-DMT (Psilacetin) modeled serum levels, 20 mg as needed (shown daily) over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 5 10 15 20 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 20 mg as needed (shown daily) (oral).

Modeled steady state after ~1 days: peak ≈ 4.5 mg, trough ≈ 0.000 mg body load. Population-based estimate over 15 days for a 20 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Psychedelic
Route modeled
Oral
Model confidence
inferred
Half-life
2.5 h
Common dose
20 mg
Reference dose range
10–40 mg (single dose)
Suggested cadence
as needed (shown daily)

Documented interactions

  • danger
    1P-LSD (1-Propionyl-LSD) + 4-AcO-DMT (Psilacetin) Serotonin risk

    1P-LSD (1-Propionyl-LSD) and 4-AcO-DMT (Psilacetin) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    25I-NBOMe + 4-AcO-DMT (Psilacetin) Serotonin risk

    25I-NBOMe and 4-AcO-DMT (Psilacetin) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    2C-I (2,5-Dimethoxy-4-iodophenethylamine) + 4-AcO-DMT (Psilacetin) Serotonin risk

    2C-I (2,5-Dimethoxy-4-iodophenethylamine) and 4-AcO-DMT (Psilacetin) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) + 4-AcO-DMT (Psilacetin) Stacked effects

    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) and 4-AcO-DMT (Psilacetin) both push the serotonin 5HT1A, serotonin 5HT2A, and serotonin 5HT2C in the same direction.

  • danger
    3-MeO-PCP (3-Methoxyphencyclidine) + 4-AcO-DMT (Psilacetin) Serotonin risk

    3-MeO-PCP (3-Methoxyphencyclidine) and 4-AcO-DMT (Psilacetin) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    5-HTP (5-Hydroxytryptophan) + 4-AcO-DMT (Psilacetin) Serotonin risk

    4-AcO-DMT (Psilacetin) and 5-HTP (5-Hydroxytryptophan) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

Serum checks 106 modeled interaction pairings for 4-aco-dmt (psilacetin) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. In vivo validation of psilacetin as a prodrug yielding modestly lower peripheral psilocin exposure than psilocybin Sherwood AM et al. · Frontiers in Psychiatry, 2024 DOI

    First in vivo validation that 4-AcO-DMT is a true psilocin prodrug, with LC-MS/MS showing ~70% relative psilocin exposure compared to equimolar psilocybin and identical ~30 min psilocin half-life.

  2. Tentative identification of in vitro metabolites of O-acetylpsilocin (psilacetin, 4-AcO-DMT) by UHPLC-Q-Orbitrap MS Zhai C et al. · Drug Testing and Analysis, 2022 DOI

    Identified 15 metabolites (12 phase I, 3 phase II) of 4-AcO-DMT using human liver microsomes, confirming deacetylation to psilocin as the primary metabolic pathway.

2 published studies referenced in the app, each with a plain-language summary.